RxSight (NASDAQ:RXST) vs. Boston Scientific (NYSE:BSX) Financial Comparison

RxSight (NASDAQ:RXST – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and price targets for RxSight and Boston Scientific, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight 2 7 2 0 2.00
Boston Scientific 2 8 20 1 2.65

RxSight presently has a consensus price target of $6.94, suggesting a potential upside of 31.01%. Boston Scientific has a consensus price target of $61.43, suggesting a potential upside of 40.47%. Given Boston Scientific’s stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than RxSight.

Insider and Institutional Ownership

78.8% of RxSight shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares RxSight and Boston Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RxSight -43.80% -20.11% -16.31%
Boston Scientific 16.62% 18.61% 10.58%

Earnings and Valuation

This table compares RxSight and Boston Scientific”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48 million 1.65 -$38.94 million ($1.28) -4.14
Boston Scientific $20.07 billion 3.16 $2.90 billion $2.36 18.53

Boston Scientific has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

RxSight has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Summary

Boston Scientific beats RxSight on 13 of the 15 factors compared between the two stocks.

About RxSight

(Get Free Report)

RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.

About Boston Scientific

(Get Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.